Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 3/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 15/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23907507 | 0.98 | NT5E (0.41) | NT5EPRMT5METTL3P2RY2P2RY6 | |
| SCHEMBL23907532 | 0.93 | P2RY2 (0.46) | NT5EPRMT5METTL3P2RY2P2RY6 | |
| SCHEMBL23907445 | 0.90 | P2RY2 (0.37) | NT5EP2RY2P2RY6P2RY4 | |
| SCHEMBL23907520 | 0.89 | NT5E (0.54) | NT5EPRMT5METTL3P2RY2P2RY6 | |
| SCHEMBL23907472 | 0.88 | NT5E (0.37) | NT5EP2RY2P2RY6P2RY4 | |
| SCHEMBL23907463 | 0.88 | NT5E (0.55) | NT5EPRMT5METTL3P2RY2P2RY6 | |
| SCHEMBL21839523 | 0.87 | NT5E (0.56) | NT5E | |
| SCHEMBL23907524 | 0.86 | NT5E (0.53) | NT5EP2RY2P2RY6P2RY4 | |
| SCHEMBL21839674 | 0.84 | NT5E (0.55) | NT5E | |
| SCHEMBL23907535 | 0.83 | ADORA3 (0.49) | NT5EP2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | NT5E 5/4885PRMT5 510/4885METTL3 1305/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885PRMT5 1413/4885METTL3 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.